3D Cell Bioprinting Consortium

What 3D Cell Bioprinting Consortium does

The 3D Cell Bioprinting Consortium is a private, for-profit group of companies founded in 2016 and headquartered in Marlborough, United States, positioned to deliver a complete tissue-engineering solution spanning the 3D cell bioprinting workflow. The consortium model aggregates capabilities from member firms rather than building a single integrated product in-house: leadership comprises Sid Braginsky (Founder) alongside senior representation from Digilab, Inc. (John Moore, President & COO) and 3-D Matrix, Inc. (Marc Rioult, Managing Director), indicating that bioprinter instrumentation and biomaterials/scaffold expertise are contributed by distinct partner organizations coordinated under the consortium umbrella.

No products, services, pricing, customer segments, distribution channels, or revenue model details are disclosed in the available data. The consortium's primary digital asset, 3dcellprinting.com, has expired and is currently listed for sale on the GoDaddy marketplace via ExpiredDomains.com at a $195 USD asking price. Wayback Machine history shows only 82 indexed pages and 12 crawls, with the domain's WHOIS birth date recorded as 19/05/2016 and first archival year of 2014. This combination of factors — lightweight consortium structure, absent commercial disclosures, and a lapsed web presence — materially limits assessment of current operating status and economic activity.

Name

3D Cell Bioprinting Consortium

Website

https://3dcellprinting.com

Company type

Private

Founded year

2016

Operating status

Operating

Short description

3D Cell Bioprinting Consortium, founded 2016 in Marlborough, US, is a private group of companies coordinating a complete tissue-engineering solution through member firms including Digilab, Inc. and 3-D Matrix, Inc.

Ownership category

akta.pro rank

Product category

Tissue Engineering

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAAAGAC

3D Bioprinting & Biofabrication

Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

SECONDARYIMAAAAAG

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)

Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

SECONDARYIMAAAJAA

Additive Manufacturing Research & Innovation Labs

Industrials, Manufacturing & Construction/3D Printing/Additive Manufacturing R&D, Training & Certification

SECONDARYHDACAEAH

3D Printers (Additive Manufacturing)

Hardware, Technology & Telecom/Computing Hardware & Peripherals/Printers, Scanners & Imaging Peripherals

Keywords

• Tissue engineering solutions
• 3D cell bioprinting
• Bioprinting technology
• Regenerative medicine
• Tissue engineering consortium

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others

Core offering

3D Cell Bioprinting Consortium is a group of companies that collectively offer a complete solution for tissue engineering. The consortium combines expertise from multiple firms in the bioprinting industry to deliver end-to-end capabilities spanning equipment, materials, and services for tissue engineering applications.

Product overview

The source data does not contain information about 3D Cell Bioprinting Consortium as a company. The content is a domain listing page from ExpiredDomains.com featuring the expired domain "3dcellprinting.com" being offered for sale at $195 USD via GoDaddy. No product, service, or company information is available in the provided source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Complete Tissue Engineering Solution End-to-end tissue engineering solution delivered through a consortium of specialized companies in the 3D cell bioprinting industry. The offering combines member-company capabilities spanning laboratory instrumentation, 3D matrix materials, and bioprinting expertise to serve biotechnology, pharmaceutical, and research customers.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Direct peers

• Aspect Biosystems: Aspect Biosystems develops microfluidic 3D bioprinting platforms and tissue therapeutics, making it a direct peer in tissue engineering and biofabrication. Its productized bioprinting systems and bioink materials overlap directly with the consortium's "complete solution" positioning.
• regenHU: regenHU manufactures bioprinting hardware and software used to fabricate tissue scaffolds and 3D cell cultures. It is a direct peer offering bioprinting systems to the same regenerative-medicine and tissue-engineering research customer base.
• Organovo Holdings: Organovo is a pioneer in 3D bioprinted human tissue constructs for research and therapeutic applications. It is directly comparable as a tissue-engineering company pursuing functional human tissue via bioprinting, addressing the same end-markets as the consortium.
• Cellink (BICO): Cellink, now operating as BICO, is a leading direct provider of 3D bioprinting hardware, bioinks, and tissue-engineering lab workflows. It is the closest direct peer to a "complete solution for tissue engineering" consortium and competes head-on for the same regenerative-medicine research customers.

Emerging players

• Poietis: Poietis is a French bioprinting company developing laser-assisted 3D bioprinting for tissue engineering and regenerative medicine. It is an emerging peer in the same bioprinting category with a more specialized technology approach.
• Inventia Life Science: Inventia Life Science provides automated 3D bioprinting platforms for cell biology and tissue engineering research. It is an emerging peer offering bioprinting instruments and protocols to the same regenerative-medicine research customer base.

Broad incumbents

• Stratasys: Stratasys is a global leader in polymer 3D printing that has invested in bioprinting research and partnered with biomaterials companies. It is comparable as a broad incumbent with adjacent biofabrication/bioprinting initiatives that overlap with the consortium's space.
• 3D Systems: 3D Systems is a broad incumbent in industrial 3D printing that has historically pursued bioprinting and tissue-engineering applications through its healthcare arm. It is comparable as a larger, diversified 3D-printing incumbent with overlapping capability in biofabrication.

Others

• 3-D Matrix, Inc. 3-D Matrix develops self-assembling peptide-based biomaterials used in tissue engineering and surgical applications. Its Managing Director is named in the consortium's leadership, making 3-D Matrix a directly affiliated rather than competing peer in the same tissue-engineering value chain.
• Digilab, Inc. Digilab is a listed member-affiliated company providing laboratory automation and instrumentation, and its President serves on the consortium's leadership per the source data. It is ecosystem-adjacent rather than a direct bioprinting competitor, but is materially comparable as a strategic member of this consortium.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3D Cell Bioprinting Consortium